首页>
外国专利>
Methods of administering a toxic dose of a mammalian vitamin compound without developing hypercalcemia and treating psoriasis, a disease selected from the group consisting of leukemia, colon cancer, breast cancer or prostate cancer, disease autoimmune disease selected from the group consisting of multiple sclerosis, lupus, inflammatory bowel disease, type i diabetes, host graft reaction, and organ transplant rejection and pharmaceutical composition
Methods of administering a toxic dose of a mammalian vitamin compound without developing hypercalcemia and treating psoriasis, a disease selected from the group consisting of leukemia, colon cancer, breast cancer or prostate cancer, disease autoimmune disease selected from the group consisting of multiple sclerosis, lupus, inflammatory bowel disease, type i diabetes, host graft reaction, and organ transplant rejection and pharmaceutical composition
"METHODS FOR ADMINISTRATION OF TOXIC DOSE OF A MAMMALIAN VITAMIN COMPOUND, WITHOUT DEVELOPMENT OF HYPERCALCEMIA, AND TREATMENT OF PSORIASIS, SELECTED DISEASE OF THE GROUP CONSISTING IN LEUKEMIA, CANCER CANCER, CANCER, CANCER, CANCER, CANCER SELECTED SELF-IMMUNE DISEASE OF THE GROUP CONSISTING OF MULTIPLE SCLEROSIS, LUPUS, INFLAMMATORY GUT DISEASE, TYPE I DIABETES, GERD REACTION AND REJECTION OF ORGAN COMPOUND TRANSPLANTS AND REJECTION Bone calcium resorption inhibitors are administered to allow high dosages of vitamin D or mimetic compounds to be given for the treatment of non-calcium related diseases such as cancer, psoriasis and autoimmune disease without the dangers of calcification of the bone. kidney, heart and aorta. Bone calcium resorption inhibitors include bisphosphonates, OPG or the soluble RANK receptor known as sRANK, and function to block the availability of calcium from bone, thereby preventing hypercalcemia and resulting tissue calcification. soft. Thus, high dosages of 1Î ±, 25-dihydroxyvitamin D -3- (1,25- (OH) -2 D-3 ~), their analogs, prodrugs or mimetics may be used with minimal patient risk. Specifically, alendronate is shown to block the bone calcium mobilization activity of both 1,25- (OH) -2-D-3 ~ and its very potent analog, 2-methylene-19-nor-20 ( S) -1?, 25-dihydroxy vitamin D?
展开▼
